Adaptive Biotechnologies (NASDAQ:ADPT) COO Julie Rubinstein Sells 11,881 Shares of Company Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) COO Julie Rubinstein sold 11,881 shares of the company’s stock in a transaction on Tuesday, October 13th. The shares were sold at an average price of $25.50, for a total transaction of $302,965.50. Following the completion of the transaction, the chief operating officer owned 377,802 shares of the company’s stock, valued at approximately $9,633,951. The trade was a 3.05% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Julie Rubinstein also recently made the following trade(s):

• On Thursday, October 8th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $25.66, for a total transaction of $304,866.46.
• On Monday, October 5th, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The stock was sold at an average price of $29.19, for a total transaction of $346,806.39.
• On Friday, October 2nd, Julie Rubinstein sold 11,881 shares of Adaptive Biotechnologies stock. The shares were sold at an average price of $28.13, for a total transaction of $334,212.53.

Adaptive Biotechnologies Stock Performance

NASDAQ ADPT opened at $25.28 on Wednesday. The company has a debt-to-equity ratio of 2.22, a current ratio of 4.79 and a quick ratio of 4.68. Adaptive Biotechnologies Corporation has a 1 year low of $12.00 and a 1 year high of $30.74. The company has a market capitalization of $4.03 billion, a PE ratio of -61.66 and a beta of 2.09. The company has a fifty day moving average of $26.12 and a two-hundred day moving average of $20.28.

Adaptive Biotechnologies (NASDAQ:ADPT) last issued its quarterly earnings data on Wednesday, July 29th. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.12). Adaptive Biotechnologies had a negative return on equity of 36.81% and a negative net margin of 20.73%. The firm had revenue of $71.55 million for the quarter, compared to analysts’ expectations of $65.44 million. During the same period in the previous year, the business posted ($0.17) EPS. The business’s revenue for the quarter was up 21.5% compared to the same quarter last year. As a group, analysts expect that Adaptive Biotechnologies Corporation will post -0.40 earnings per share for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. BlackRock Inc. purchased a new position in shares of Adaptive Biotechnologies during the second quarter worth about $324,735,000. Wellington Management Group LLP raised its stake in Adaptive Biotechnologies by 53.2% during the 2nd quarter. Wellington Management Group LLP now owns 5,911,366 shares of the company’s stock valued at $126,799,000 after acquiring an additional 2,053,944 shares during the last quarter. Bank of America Corp DE purchased a new stake in Adaptive Biotechnologies during the 2nd quarter valued at approximately $37,109,000. Principal Financial Group Inc. raised its stake in Adaptive Biotechnologies by 9.8% during the 1st quarter. Principal Financial Group Inc. now owns 1,704,887 shares of the company’s stock valued at $23,664,000 after acquiring an additional 152,378 shares during the last quarter. Finally, Freestone Grove Partners LP purchased a new stake in Adaptive Biotechnologies during the 2nd quarter valued at approximately $18,912,000. 99.17% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on ADPT. BTIG Research raised their price target on Adaptive Biotechnologies from $25.00 to $34.00 and gave the stock a “buy” rating in a research note on Tuesday, September 22nd. Weiss Ratings reiterated a “sell (d-)” rating on shares of Adaptive Biotechnologies in a research note on Friday, July 17th. Guggenheim boosted their price objective on Adaptive Biotechnologies from $25.00 to $32.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. National Bank Financial set a $34.00 price objective on Adaptive Biotechnologies in a report on Tuesday, September 22nd. Finally, TD Cowen raised their target price on shares of Adaptive Biotechnologies from $28.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday. Six equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $30.06.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a biotechnology company focused on using the genetics of the adaptive immune system to develop diagnostic and therapeutic applications. Its technologies analyze immune-cell receptors, including T-cell and B-cell receptors, to help identify and measure immune responses associated with cancer, infectious diseases and other conditions.

The company’s product portfolio includes immunoSEQ, a research and clinical platform for immune-repertoire sequencing, and clonoSEQ, a diagnostic test used to detect and monitor measurable residual disease in certain blood cancers.